Text Size

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00088465
First received: July 26, 2004
Last updated: December 9, 2011
Last verified: December 2011
History of Changes
Results First Received: October 14, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Schizophrenic Disorders
Schizoaffective Disorder
Intervention: Drug: Intramuscular olanzapine depot

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Intramuscular Olanzapine Depot Intramuscular (IM) olanzapine depot flexible dosing and flexible interval

Participant Flow:   Overall Study
    Intramuscular Olanzapine Depot  
STARTED     931  
COMPLETED     370  
NOT COMPLETED     561  
Withdrawal by Subject                 290  
Adverse Event                 77  
Lost to Follow-up                 57  
Physician Decision                 45  
Sponsor Decision                 37  
Lack of Efficacy                 27  
Protocol Violation                 17  
Death                 11  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Intramuscular Olanzapine Depot Intramuscular (IM) olanzapine depot flexible dosing and flexible interval

Baseline Measures
    Intramuscular Olanzapine Depot  
Number of Participants  
[units: participants]
 		  931  
Age  
[units: years]
Mean ± Standard Deviation 		  39.32  ± 11.67  
Gender  
[units: participants]
 		 
Female     310  
Male     621  
Race/Ethnicity, Customized  
[units: participants]
 		 
African     102  
Caucasian     629  
East Asian     39  
Hispanic     140  
Native American     2  
West Asian     19  
Region of Enrollment  
[units: participants]
 		 
United States     177  
Portugal     18  
Taiwan     30  
Slovakia     13  
Spain     24  
Russian Federation     114  
Israel     29  
Italy     6  
France     55  
Puerto Rico     27  
Australia     11  
South Africa     28  
Netherlands     8  
Austria     10  
Czech Republic     3  
Hungary     13  
Mexico     63  
Argentina     73  
Poland     33  
Brazil     89  
Belgium     13  
Croatia     16  
Romania     34  
Germany     32  
Sweden     9  
Greece     3  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Adverse Events (AE)   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 1

2.  Primary:   Number of Participants With Treatment-Emergent Abnormal High Prolactin at Any Time Post Baseline   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 2

3.  Primary:   Number of Participants With Treatment-Emergent Abnormal High Alanine Transaminase (ALT), High Aspartate Transaminase (AST), High Total Bilirubin at Any Time Post Baseline   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 3

4.  Primary:   Number of Participants Having Normal Fasting Baseline Glucose Value With Treatment-Emergent High Fasting Glucose at Any Time Post Baseline   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 4

5.  Primary:   Number of Participants Having Normal Fasting Baseline Lipid Value With Treatment-Emergent High Fasting Lipid at Any Time Post Baseline   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 5

6.  Primary:   Change From Baseline in Weight at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 6

7.  Primary:   Number of Participants With Potentially Clinically Significant (PCS) Weight Gain at Month 76 Endpoint   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 7

8.  Primary:   Number of Participants With Extrapyramidal Symptoms at Any Time   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 8

9.  Secondary:   Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 9

10.  Secondary:   Change From Baseline in PANSS Positive Scores at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 10

11.  Secondary:   Change From Baseline in PANSS Negative Scores at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 11

12.  Secondary:   Change From Baseline in PANSS General Psychopathology Subscales at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 12

13.  Secondary:   Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Scores at Month 72 Endpoint   [ Time Frame: Baseline, up to 72 months ]
  Show Outcome Measure 13

14.  Secondary:   Change From Baseline in the Heinrichs-Carpenter Quality of Life Scale (QLS) Total Score at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 14

15.  Secondary:   Change From Baseline in 36-Item Short Form Health Survey (SF-36) at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 15

16.  Secondary:   Number of Psychiatric Visits   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 16

17.  Secondary:   Days of Hospitalization   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 17

18.  Secondary:   Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) at Month 76 Endpoint   [ Time Frame: Baseline, up to 76 months ]
  Show Outcome Measure 18

19.  Secondary:   Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint   [ Time Frame: Randomization to end of study up to 76 months ]
  Hide Outcome Measure 19

Measure Type Secondary
Measure Title Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint
Measure Description Self-rated scale that measures patient's level of satisfaction with current antipsychotic medication. Consists of 3 items assessing satisfaction with current study medication (scored from 1='very dissatisfied' to 5='very satisfied'), preference comparing current study medication versus previous medications (scored from 1='much prefer previous medication' to 5='much prefer study medication'), and side effects of current study medication compared with previous medications (scored from 1='much less side effects' to 5='much more side effects'). Range of possible scores is 3-15.
Time Frame Randomization to end of study up to 76 months  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All randomized participants.

Reporting Groups
  Description
Intramuscular Olanzapine Depot Intramuscular (IM) olanzapine depot flexible dosing and flexible interval

Measured Values
    Intramuscular Olanzapine Depot  
Number of Participants Analyzed  
[units: participants]
 		  931  
Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint  
[units: percent of participants]
 		 
Depot, somewhat or very satisfied     73.2  
Depot vs. oral, prefer or much prefer     66.8  
Depot vs. oral, less or much less side effects     73.3  

No statistical analysis provided for Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint



20.  Secondary:   Plasma Olanzapine Concentrations in Participants During Long-Term Treatment by Year   [ Time Frame: Randomization to end of study up to 76 months ]
  Show Outcome Measure 20


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 800-545-5979


No publications provided by Eli Lilly and Company

Publications automatically indexed to this study:


Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00088465     History of Changes
Other Study ID Numbers: 5995, F1D-MC-HGKB
Study First Received: July 26, 2004
Results First Received: October 14, 2011
Last Updated: December 9, 2011
Health Authority: United States: Food and Drug Administration